"The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, ...
The MarketWatch News Department was not involved in the creation of this content. BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage ...
TransCode Therapeutics Inc. (NASDAQ:RNAZ) said it has secured a financing agreement with an institutional healthcare investor that could provide the company with up to $20 million in funding. The ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results